ScholarLens Back to search
2013•Clinical Pharmacology & TherapeuticsRequires access

Novel Therapeutics for the Treatment of Familial Mediterranean Fever: From Colchicine to Biologics

I. Grattagliano, Leonilde Bonfrate, Valentina Ruggiero, Giuseppe Scaccianoce, Giuseppe Palasciano, Piero Portincasa

Open publisher page 74 citations

Abstract

Familial Mediterranean fever (FMF), an inherited autosomal recessive disorder, is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1–3 days. Patients may develop renal amyloidosis, arthritis, serositis, and skin and oral lesions. Diagnosis is based on clinical features, response to treatment with colchicine, and genetic analysis. Colchicine prevents attacks and renal amyloidosis, in addition to reversing proteinuria. Nonresponders may receive novel therapy, including interleukin (IL)-1 receptor antagonists and IL-1 decoy receptor. Recently, new options have been considered. Clinical Pharmacology & Therapeutics (2013); 95 1, 89–97 advance online publication 2 October 2013. doi:10.1038/clpt.2013.148

About this research paper

What this paper is about

Familial Mediterranean fever (FMF), an inherited autosomal recessive disorder, is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1–3 days. Patients may develop renal amyloidosis, arthritis, serositis, and skin and oral lesions. Diagnosis is based on clinical features, response to treatment with colchicine, and genetic analysis. Colchicine prevents attacks and renal amyloidosis, in addition to reversing proteinuria. Nonresponders may receive novel therapy, including interleukin (IL)-1 receptor antagonists and IL-1 decoy receptor. Recently, new options have been considered. Clinical Pharmacology & Therapeutics (2013); 95 1, 89–97 advance online publication 2 October 2013. doi:10.1038/clpt.2013.148

Why it matters

OpenAlex reports 74 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Familial Mediterranean fever (FMF), an inherited autosomal recessive disorder, is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1–3 days. Patients may develop renal amyloidosis, arthritis, serositis, and skin and oral lesions. Diagnosis is based on clinical features, response to treatment with colchicine, and genetic analysis. Colchicine prevents attacks and renal amyloidosis, in addition to reversing proteinuria. Nonresponders may receive novel therapy, including interleukin (IL)-1 receptor antagonists and IL-1 decoy receptor. Recently, new options have been considered. Clinical Pharmacology & Therapeutics (2013); 95 1, 89–97 advance online publication 2 October 2013. doi:10.1038/clpt.2013.148

Key concepts: Familial Mediterranean fever, Colchicine, Serositis, Medicine, Canakinumab, AA amyloidosis, Anakinra, Amyloidosis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Novel Therapeutics for the Treatment of Familial Mediterranean Fever: From Colchicine to Biologics — Research Paper | ScholarLens